Insights from the ASCO GU Cancers Symposium

Andrea Apolo, MD, National Cancer Institute

Conference Coverage

Adjuvant Pembrolizumab New Therapeutic Option For High-Risk Muscle-Invasive Bladder Cancer

02/05/2024

At the 2024 ASCO GU Cancers Symposium, Andrea Apolo, MD, shared insights from the phase 3 AMBASSADOR Alliance AO31501 study, looking at adjuvant pembrolizumab for patients with muscle-invasive bladder cancer at a high risk for recurrence.

At the 2024 ASCO GU Cancers...

02/05/2024

Oncology

Conference Coverage

Real-World Response to Apalutamide vs Enzalutamide for Metastatic Castration-Resistant Prostate Cancer

01/31/2024

Benjamin Lowentritt , MD;

Benjamin Lowentritt share results from a study of real-world data which found more patients with metastatic castration-resistant prostate cancer had a deep, early PSA response to apalutamide than enzalutamide.

Benjamin Lowentritt share...

01/31/2024

Oncology

Conference Coverage

Cabozantinib Plus Atezolizumab Showed Modest Activity Among Patients With Advanced Adrenocortical Carcinoma

01/31/2024

Enrique Grande , MD, PhD;

Enrique Grande, MD, shared results from the phase 2 CABATEN study, which evaluated the activity and safety of cabozantinib plus atezolizumab among patients with locally advanced or metastatic adrenocortical carcinoma.

Enrique Grande, MD, shared...

01/31/2024

Oncology

Conference Coverage

Nivolumab Plus Ipilimumab Improved Survival, Response Compared to Sunitinib Among Patients With Advanced Clear Cell Renal Cell Carcinoma

01/31/2024

Stephanie Holland ;

Long-term follow-up data from the phase 3 CheckMate-214 trial demonstrated that nivolumab plus ipilimumab improved survival and response compared to sunitinib among patients with advanced renal cell carcinoma.

Long-term follow-up data from...

01/31/2024

Oncology

Conference Coverage

HER2 and PD-L1 Immunohistochemistry Expression Among Patients With Advanced Bladder Cancer

01/30/2024

David Aggen , MD, PhD;

David Aggen, MD, shares insights from a retrospective analysis done to evaluate the association between HER2 mutation/amplification, HER2, and PD-L1 immunohistochemistry expression, and associations with clinical outcomes for advanced bladder...

David Aggen, MD, shares insights...

01/30/2024

Oncology

Conference Coverage

Belzutifan Improves Quality of Life Among Patients With Advanced Clear Cell Renal Cell Carcinoma

01/27/2024

Thomas Powles , MBBS, MD;

Thomas Powles, MBBS, MD, discusses results from the phase 3 LITESPARK-005 study which compared patient-reported outcomes among patients treated with belzutifan and everolimus for advanced/metastatic clear cell renal cell carcinoma.

Thomas Powles, MBBS, MD,...

01/27/2024

Oncology

Conference Coverage

Adjuvant Pembrolizumab Succeeds For Patients With Renal Cell Carcinoma At Increased Risk of Relapse

01/27/2024

Allison Casey ;

Adjuvant pembrolizumab significantly improved overall survival among patients with renal cell carcinoma at an increased risk for recurrence after surgery, when compared with placebo.

Adjuvant pembrolizumab...

01/27/2024

Oncology

Conference Coverage

Adjuvant Nivolumab Failed to Meet End Point for Patients With Renal Cell Carcinoma

01/27/2024

Allison Casey ;

In Part B of CheckMate 914, adjuvant nivolumab monotherapy failed to meet the primary end point of disease-free survival for patients with renal cell carcinoma at high risk of relapse following nephrectomy.

In Part B of CheckMate 914,...

01/27/2024

Oncology

Conference Coverage

Subcutaneous Nivolumab Noninferior to Intravenous Administration Among Patients With Clear Cell Renal Cell Carcinoma

01/27/2024

Saby George , MD;

Saby George shares insights from the CheckMate 67T evaluating the subcutaneous administration of nivolumab for patients with clear cell renal cell carcinoma, compared with the intravenous administration.

Saby George shares insights from...

01/27/2024

Oncology

Conference Coverage

Enfortumab Vedotin Plus Pembrolizumab Potential New Standard of Care for Advanced Urothelial Carcinoma in the First-Line Setting

01/26/2024

Michiel van der Heijden , MD;

Michiel van der Heijden, MD, discusses the subgroup analyses of the phase 3 EV-302 study, evaluating enfortumab vedotin plus pembrolizumab among patients with locally advanced or metastatic urothelial carcinoma in the first-line setting.

Michiel van der Heijden, MD,...

01/26/2024

Oncology

Conference Coverage

Adjuvant Pembrolizumab Improved Disease-Free Survival Among Patients With Muscle-Invasive Bladder Cancer

01/26/2024

Stephanie Holland ;

Interim DFS/OS results from the phase 3 AMBASSADOR Alliance AO31501 study demonstrated adjuvant pembrolizumab improved DFS among patients with high-risk muscle-invasive urothelial carcinoma.

Interim DFS/OS results from the...

01/26/2024

Oncology

Neal Shore, MD, Carolina Urologic Research Center

Conference Coverage

Impact of Suspended Enzalutamide Monotherapy on Metastasis-Free Survival Among Patients With High-Risk Biochemically Recurrent Prostate Cancer

01/26/2024

Neal Shore , MD, FACS;

Neal Shore, MD, discusses results from the phase 3 EMBARK trial, evaluating treatment suspension among patients with high-risk biochemically recurrent prostate cancer.

Neal Shore, MD, discusses...

01/26/2024

Oncology

Conference Coverage

Oral APL-1202 Plus Tislelizumab Shows Promise in Neoadjuvant Setting Among Patients With Muscle-Invasive Bladder Cancer

01/26/2024

Allison Casey ;

According to results from a phase 1/2 study, the combination of oral APL-1202 and tislelizumab in the neoadjuvant setting showed promising activity and safety among patients with muscle-invasive bladder cancer.

According to results from a...

01/26/2024

Oncology

Conference Coverage

Cognitive Function Similar Between Patients With mCRPC Treated With Abiraterone Acetate or Enzalutamide

01/25/2024

Stephanie Holland ;

Results from the ACE study suggest that patients with metastatic castration-resistant prostate cancer treated with either abiraterone acetate or enzalutamide have a comparable composite cognitive outcome, though patients treated with...

Results from the ACE study...

01/25/2024

Oncology

Conference Coverage

Olaparib Plus Abiraterone and Prednisone Improved Progression-Free Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and HRR Mutations

01/25/2024

Allison Casey ;

According to a phase 2 trial, olaparib plus abiraterone/prednisone improved the progression-free survival among patients with metastatic castration-resistant prostate cancer with BRCA1/2 or ATM mutations, compared to either agent alone or...

According to a phase 2 trial,...

01/25/2024

Oncology

Conference Coverage

Cabozantinib Plus Atezolizumab Significantly Prolonged PFS in Metastatic Castration-Resistant Prostate Cancer

01/25/2024

Stephanie Holland ;

Results from the ongoing phase 3 CONTACT-2 trial demonstrated that cabozantinib plus atezolizumab significantly improved rPFS compared to abiraterone plus prednisone or enzalutamide among patients with metastatic castration-resistant prostate...

Results from the ongoing phase 3...

01/25/2024

Oncology

Conference Coverage

Dose-Escalated Radiotherapy Plus Long-Term Androgen-Deprivation Therapy Deemed Safe, Effective for High-Risk Prostate Cancer

01/25/2024

Allison Casey ;

According to a phase 3 trial, dose-escalated radiotherapy combined with long-term androgen deprivation therapy improved the survival outcomes, without increasing toxicities, among patients with high-risk prostate cancer.

According to a phase 3 trial,...

01/25/2024

Oncology

News

Nivolumab Plus Chemotherapy Following TURBT for Patients With Muscle-Invasive Bladder Cancer

05/02/2023

Allison Casey ;

According to a phase 2 study, post-TURBT gemcitabine-cisplatin plus nivolumab conveyed a high complete response rate for patients with muscle-invasive bladder cancer, with many responders going on to achieve 2-year bladder-intact...

According to a phase 2 study,...

05/02/2023

Oncology

Videos

No Improvement to Survival Outcomes With Pembrolizumab Plus Docetaxel for Castration-Resistant Prostate Cancer

03/10/2023

Daniel Petrylak, MD, discusses an abstract presented at 2023 ASCO Genitourinary Cancers Symposium, evaluating pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer.

Daniel Petrylak, MD, discusses...

03/10/2023

Oncology

Neeraj Agarwal, MD, Huntsman Cancer Institute

Videos

Talazoparib Plus Enzalutamide Improves PFS in Metastatic Castration-Resistant Prostate Cancer

03/08/2023

At the 2023 ASCO Genitourinary Cancers Symposium, Neeraj Agarwal, MD, presented results from a phase 3 trial evaluating enzalutamide plus talazoparib vs enzalutamide plus placebo for patients with metastatic castration-resistant prostate...

At the 2023 ASCO Genitourinary...

03/08/2023

Oncology

Siamak Daneshmand, MD, Norris Comprehensive Cancer Center at USC

Videos

Erdafitinib for Patients With Intermediate-Risk Non-Muscle Invasive Bladder Cancer

03/02/2023

At the 2023 ASCO GU Cancers Symposium, Siamak Daneshmand, MD, reported interim analysis results from Cohort 3 of the phase 2 THOR-2 trial.

At the 2023 ASCO GU Cancers...

03/02/2023

Oncology

Nicholas Van As, MMBCh, Royal Marsden Hospital

Videos

Quality of Life Outcomes: SBRT vs Surgery for Patients with Localized Prostate Cancer

03/02/2023

At the 2023 ASCO GU Cancers Symposium, Nicholas Van As, MMBCh, discusses the results from the PACE-A trial, comparing quality of life outcomes from surgery vs SBRT with localized prostate cancer.

At the 2023 ASCO GU Cancers...

03/02/2023

Oncology

James Catto, MB, ChB, PhD, University of Sheffield

Videos

Erdafitinib for Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

03/02/2023

At the 2023 ASCO GU Cancers Symposium, James Catto, MB, ChB, PhD, discusses results from Cohort 2 of a phase 2 trial evaluating erdafitinib among patients with bacillus Calmette-Guérin (BCG)-unresponsive, high risk, non-muscle-invasive...

At the 2023 ASCO GU Cancers...

03/02/2023

Oncology

Daniel Geynisman, MD, Fox Chase Cancer Center

Videos

Risk-Adapted Approach for Muscle-Invasive Bladder Cancer Requires Further Refinement

03/01/2023

At the 2023 ASCO GU Cancers Symposium, Daniel Geynisman, MD, shares results of a trial examining a risk-adapted approach to treatment for patients with muscle-invasive bladder cancer.

At the 2023 ASCO GU Cancers...

03/01/2023

Oncology

Srikala Sridhar, MD, Princess Margaret Cancer Center

Videos

Avelumab Maintenance for Urothelial Carcinoma by First-Line Chemotherapy Regimen

02/28/2023

At the 2023 ASCO GU Cancers Symposium, Srikala Sridhar, MD, shares results and insights from the long-term follow-up of the JAVELIN Bladder 001 trial.

At the 2023 ASCO GU Cancers...

02/28/2023

Oncology

Gwenaelle Gravis, MD, Institute Paoli-Calmettes

Videos

Safety of Apalutamide vs Active Surveillance for Prostate Cancer

02/27/2023

At 2023 ASCO Genitourinary Cancers Symposium, Gwenaelle Gravis, MD, presented a study evaluating the addition of apalutamide to active surveillance for patients with low to intermediate risk prostate cancer.

At 2023 ASCO Genitourinary...

02/27/2023

Oncology

Eleni Efstathiou, MD, Houston Methodist Cancer Center

Videos

Niraparib Plus Abiraterone and Prednisone for Patients With Castration-Resistant Prostate Cancer and HRR Alterations

02/27/2023

At 2023 ASCO Genitourinary Cancers Symposium, Eleni Efstathiou, MD, shared phase 3 data which support the use of niraparib with abiraterone acetate and prednisone among patients with metastatic castration-resistant prostate cancer and BRCA...

At 2023 ASCO Genitourinary...

02/27/2023

Oncology

Conference Coverage

Radiolabeled 89Zr-DFO-girentuximab PET/CT Imaging Accurately Identifies Clear Cell Renal Cell Carcinoma

02/22/2023

Allison Casey ;

According to phase 3 results presented at the 2023 ASCO GU Cancers Symposium, radiolabeled 89Zr-DFO-girentuximab (TLX250-CDx) PET/CT was able to accurately identify clear cell renal cell carcinoma.

According to phase 3 results...

02/22/2023

Oncology

Conference Coverage

Neoadjuvant Chemotherapy Plus Radical Cystectomy Superior to Trimodality Therapy for Early-Stage Small Cell Bladder Cancer

02/22/2023

Mellanie True Hills ;

According to results presented at the 2023 ASCO GU Cancers Symposium, neoadjuvant chemotherapy plus radical cystectomy improved overall survival rates among patients with early-stage small cell bladder cancer compared to trimodality therapy.

According to results presented...

02/22/2023

Oncology

Conference Coverage

Nivolumab Plus Cabozantinib Benefits Consistent at 3 Years for Renal Cell Carcinoma

02/21/2023

Allison Casey ;

According to 3-year follow-up data presented at the 2023 ASCO GU Symposium, nivolumab plus cabozantinib continues to demonstrate benefits in survival and response for patients with advanced renal cell carcinoma, compared with sunitinib.

According to 3-year follow-up...

02/21/2023

Oncology

Conference Coverage

Sacituzumab Govitecan Improved Response Rate Among Platinum-Ineligible Patients With Urothelial Carcinoma

02/21/2023

Mellanie True Hills ;

According to results presented at the 2023 ASCO GU Cancers Symposium, sacituzumab govitecan monotherapy resulted in heightened response rates among platinum-ineligible patients with metastatic urothelial carcinoma who progressed following...

According to results presented...

02/21/2023

Oncology

Andrew Katims, MD, Memorial Sloan Kettering Cancer Center

Videos

Assessing the MSK-ACCESS ctDNA Assay in Node-Positive Muscle-Invasive Bladder Cancer

02/21/2023

At the 2023 ASCO GU Cancers Symposium, Andrew Katims, MD, presents results from an assessment of a ctDNA assay in node-positive muscle-invasive bladder cancer.

At the 2023 ASCO GU Cancers...

02/21/2023

Oncology

Kyle Rose, MD, Moffitt Cancer Center & Research Institute

Videos

Urinary Tumor DNA for Minimal Residual Disease Detection at Repeat TURBT in Non-Muscle-Invasive Bladder Cancer

02/21/2023

At the 2023 ASCO GU Cancers Symposium, Kyle Rose, MD, presents results from a prospective study investigating urinary tumor DNA as a surrogate for minimal residual disease among patients with NMIBC undergoing repeat TURBT.

At the 2023 ASCO GU Cancers...

02/21/2023

Oncology

Conference Coverage

Abiraterone Plus Olaparib Prolonged rPFS, Improved OS Among Patients With Castration-Resistant Prostate Cancer

02/17/2023

Mellanie True Hills ;

According to results presented at the 2023 ASCO GU Cancers Symposium, the randomized, double-blind, phase 3 PROpel study found abiraterone acetate plus olaparib prolonged radiographic progression-free survival and improved overall survival...

According to results presented...

02/17/2023

Oncology

Conference Coverage

Tislelizumab Plus Radiotherapy for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

02/17/2023

Allison Casey ;

According to preliminary results from a phase 2 trial presented at the 2023 ASCO GU Symposium, tislelizumab plus radiotherapy shows promise as a bladder-preserving therapy for BCG-unresponsive patients with non-muscle-invasive bladder cancer...

According to preliminary results...

02/17/2023

Oncology

Conference Coverage

Nivolumab Benefit Continues At 3 Years for Muscle-Invasive Urothelial Carcinoma Post-Resection

02/17/2023

Allison Casey ;

According to follow-up data presented at the 2023 ASCO GU Cancers Symposium, nivolumab continued to show benefit in survival outcomes among patients with high-risk muscle-invasive urothelial carcinoma after radical resection.

According to follow-up data...

02/17/2023

Oncology

Aristotelis Bamias, MD, University of Athens

Videos

Atezolizumab Monotherapy vs Chemotherapy for Patients with Metastatic Urothelial Carcinoma

02/17/2023

At the 2023 ASCO Genitourinary Cancer Symposium, Aristotelis Bamias, MD, discusses overall survival results from the IMvigor130 study, evaluating atezolizumab monotherapy and platinum/gemcitabine chemotherapy among previously untreated...

At the 2023 ASCO Genitourinary...

02/17/2023

Oncology

Conference Coverage

Pembrolizumab Monotherapy Shows Activity Among BCG-Unresponsive Patients With Non-CIS, Papillary NMIBC

02/17/2023

Allison Casey ;

According to study results presented at the 2023 ASCO GU Cancers Symposium, pembrolizumab monotherapy showed antitumor activity for patients with non-carcinoma in situ, papillary, high-risk non-muscle-invasive bladder cancer who were...

According to study results...

02/17/2023

Oncology

Conference Coverage

Neoadjuvant Chemotherapy Plus Tislelizumab Followed by Radiotherapy As Bladder-Preserving Treatment for Muscle-Invasive Urothelial Bladder Cancer

02/17/2023

Allison Casey ;

According to study results presented at the 2023 ASCO GU Cancers Symposium, neoadjuvant chemotherapy plus tislelizumab followed by radiation for patients with muscle-invasive bladder cancer showed perfect efficacy and acceptable tolerability.

According to study results...

02/17/2023

Oncology

Conference Coverage

Neoadjuvant Pembrolizumab Plus Chemotherapy to Induce Tumor Down-Staging for Muscle-Invasive Urothelial Carcinoma

02/17/2023

Allison Casey ;

According to phase 1b/2 trial results presented at the 2023 ASCO Genitourinary Cancers Symposium, neoadjuvant chemo-immunotherapy resulted in down-staging prior to definitive surgery for patients with muscle-invasive urothelial carcinoma,...

According to phase 1b/2 trial...

02/17/2023

Oncology

Scott Tagawa, MD, Weill Cornell Medicine

Videos

Anti-PSMA Salvage Radio-Immunotherapy for Castration-Resistant Prostate Cancer

02/16/2023

Scott Tagawa, MD, presents results from a phase 2 study evaluating anti-PSMA salvage radio-immunotherapy for patients with high-risk non-metastatic castration-resistant prostate cancer.

Scott Tagawa, MD, presents...

02/16/2023

Oncology

Conference Coverage

Talazoparib Plus Enzalutamide Improves PFS for Metastatic Castration-Resistant Prostate Cancer

02/16/2023

Allison Casey ;

According to phase 3 interim data presented at the 2023 ASCO GU Symposium, talazoparib plus enzalutamide was superior to standard-of-care enzalutamide in imaging-based progression-free survival for patients with metastatic...

According to phase 3 interim...

02/16/2023

Oncology

Conference Coverage

Rucaparib Improved Survival Outcomes vs Docetaxel and Androgen Pathway Inhibitor Therapy Among Patients with Metastatic Castration-Resistant Prostate Cancer

02/16/2023

Allison Casey ;

According to phase 3 interim data presented at the 2023 ASCO GU Symposium, rucaparib improved radiographic progression-free survival vs either docetaxel or abiraterone/enzalutamide for patients with metastatic castration-resistant prostate...

According to phase 3 interim...

02/16/2023

Oncology

Conference Coverage

Darolutamide Plus ADT and Docetaxel As a New Standard of Care for Hormone-Sensitive Prostate Cancer

02/16/2023

Allison Casey ;

According to phase 3 trial data presented at the 2023 ASCO GU Symposium, darolutamide plus androgen-deprivation therapy and docetaxel improved the overall survival of patients with metastatic hormone-sensitive prostate cancer regardless of...

According to phase 3 trial data...

02/16/2023

Oncology

Conference Coverage

BXCL701/Talabostat As a Treatment Option for Refractory Metastatic Castration-Resistant Prostate Cancer of Small Cell Neuroendocrine Phenotype

02/16/2023

Allison Casey ;

According to phase 2a trial results presented at the 2023 ASCO GU Symposium, the oral small molecule inhibitor of dipeptidyl peptidases, BXCL701, showed promise among patients with refractory metastatic castration-resistant prostate cancer of...

According to phase 2a trial...

02/16/2023

Oncology

Insights from the ASCO GU Cancers Symposium

Specialties

Events

Year Round Education

HMP Global Products